150 related articles for article (PubMed ID: 19323060)
1. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
Stettner R; Bogusiewicz M; Rechberger T
Ginekol Pol; 2009 Jan; 80(1):47-53. PubMed ID: 19323060
[TBL] [Abstract][Full Text] [Related]
2. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
Rauvala M; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
4. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
Gershtein ES; Levkina NV; Digayeva MA; Laktionov KP; Tereshkina IV; Kushlinsky NE
Bull Exp Biol Med; 2010 Oct; 149(5):628-31. PubMed ID: 21165404
[TBL] [Abstract][Full Text] [Related]
6. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma gelatinase A (MMP-2) activity is associated with quiescent Crohn's Disease.
Kossakowska AE; Medlicott SA; Edwards DR; Guyn L; Stabbler AL; Sutherland LR; Urbanski SJ
Ann N Y Acad Sci; 1999 Jun; 878():578-80. PubMed ID: 10415778
[No Abstract] [Full Text] [Related]
8. Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis.
Bieniaś B; Sikora P
Dis Markers; 2020; 2020():9520309. PubMed ID: 32670438
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
10. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
11. [Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation.].
Kim LB; Russkih GS; Putyatina AN; Tsypysheva OB
Adv Gerontol; 2018; 31(2):223-230. PubMed ID: 30080329
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
13. Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2.
Rossignol P; Jacob MP; Cambillau M; Mouradian D; Plouin PF; Chatellier G
Thromb Res; 2007; 119(2):261-3. PubMed ID: 16530811
[No Abstract] [Full Text] [Related]
14. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
18. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
[TBL] [Abstract][Full Text] [Related]
19. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
